The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abelacimab for Prevention of Venous Thromboembolism
Open accessAbstract
BACKGROUND: The role of factor XI in the pathogenesis of postoperative venous thromboembolism is uncertain. Abelacimab is a monoclonal antibody that binds to factor XI and locks it in the zymogen (inactive precursor) conformation. METHODS: In this open-label, parallel-group trial, we randomly assigned 412 patients who were undergoing total knee arthroplasty to receive one of three regimens of abelacimab (30 mg, 75 mg, or 150 mg) administered postoperatively in a single intravenous dose or to receive 40 mg of enoxaparin administered subcutaneously once daily. The primary efficacy outcome was venous thromboembolism, detected by mandatory venography of the leg involved in the operation or objective confirmation of symptomatic events. The principal safety outcome was a composite of major or clinically relevant nonmajor bleeding up to 30 days after surgery. RESULTS: Venous thromboembolism occurred in 13 of 102 patients (13%) in the 30-mg abelacimab group, 5 of 99 patients (5%) in the 75-mg abelacimab group, and 4 of 98 patients (4%) in the 150-mg abelacimab group, as compared with 22 of 101 patients (22%) in the enoxaparin group. The 30-mg abelacimab regimen was noninferior to enoxaparin, and the 75-mg and 150-mg abelacimab regimens were superior to enoxaparin (P<0.001). Bleeding occurred in 2%, 2%, and none of the patients in the 30-mg, 75-mg, and 150-mg abelacimab groups, respectively, and in none of the patients in the enoxaparin group. CONCLUSIONS: This trial showed that factor XI is important for the development of postoperative venous thromboembolism. Factor XI inhibition with a single intravenous dose of abelacimab after total knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. (Funded by Anthos Therapeutics; ANT-005 TKA EudraCT number, 2019-003756-37.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Triggers, targets and treatments for thrombosis
Mackman, N. (2008) · Nature · doi:10.1038/nature06797 · Cited by 1,188
Defective thrombus formation in mice lacking coagulation factor XII
Renné, T., Pozgajová, M., Grüner, S., Schuh, K., Pauer, H.-U., Burfeind, P., Gailani, D., & Nieswandt, B. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050664 · Cited by 683
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Büller, H. R., Bethune, C., Bhanot, S., Gailani, D., Monia, B. P., Raskob, G. E., Segers, A., Verhamme, P., & Weitz, J. I. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1405760 · Cited by 630
Self-citationKoch, A. W., Schiering, N., Melkko, S., Ewert, S., Salter, J., Zhang, Y., McCormack, P., Yu, J., Huang, X., Chiu, Y., et al. (2019) · Blood · doi:10.1182/blood-2018-10-880849 · Cited by 139
Self-citationFuji, T., FUJITA, S., TACHIBANA, S., & Kawai, Y. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04021.x · Cited by 137
Cited by
Stroke genetics informs drug discovery and risk prediction across ancestries
Mishra, A., Malik, R., Hachiya, T., Jürgenson, T., Namba, S., Posner, D. C., Kamanu, F. K., Koido, M., Le Grand, Q., Shi, M., et al. (2022) · Nature · doi:10.1038/s41586-022-05165-3 · Cited by 600
Milvexian for the Prevention of Venous Thromboembolism
Weitz, J. I., Strony, J., Ageno, W., Gailani, D., Hylek, E. M., Lassen, M. R., Mahaffey, K. W., Notani, R. S., Roberts, R., Segers, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113194 · Cited by 269
Self-citationKumbhani, D. J., Armbruster, A. L., Cheng, R. K., Chrispin, J., Fischer, U., Holbrook, A. M., Joglar, J., & Sevestre, M.-A. (2026) · JACC · doi:10.1016/j.jacc.2026.05.033 · Cited by 2
Metadata
- Authors
- Verhamme, P., Yi, B. A., Segers, A., Salter, J., Bloomfield, D., Büller, H. R., Raskob, G. E., & Weitz, J. I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-12
- Volume
- 385
- Issue
- 7
- Pages
- 609-617
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3186384071
- Cited by
- 306
- References
- 7
- FWCI
- 35.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abelacimab for Prevention of Venous Thromboembolism. https://app.cochat.ai/papers/10.1056/nejmoa2105872
- The paper
- Verhamme, P., Yi, B. A., Segers, A., Salter, J., Bloomfield, D., Büller, H. R., Raskob, G. E., & Weitz, J. I. (2021). Abelacimab for Prevention of Venous Thromboembolism. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2105872
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.